A. Callegari , M. Albertini , L. Iserin , D. Bonnet , S. Malekzadeh-Milani
{"title":"急性右心室流出道(RVOT)感染性心内膜炎的介入治疗,为手术或经皮肺动脉瓣植入术架起桥梁","authors":"A. Callegari , M. Albertini , L. Iserin , D. Bonnet , S. Malekzadeh-Milani","doi":"10.1016/j.acvd.2024.07.029","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Infectious endocarditis (IE) is life threatening after pulmonary valve replacement. In case of obstructive cardiogenic shock or severe RVOTO an emergency percutaneous treatment can allow clinical stabilization to delay valve replacement.</p></div><div><h3>Objective</h3><p>This study aims to assess procedural success and clinical outcome in 16 consecutive patients (mean<!--> <!-->±<!--> <!-->SD age 27.2<!--> <!-->±<!--> <!-->15.7) with IE and primary percutaneous treatment.</p></div><div><h3>Methods</h3><p>Patients were retrospectively included.</p></div><div><h3>Results</h3><p>IE affected a Melody® valve in 9/16 (57%) cases (3/9 in a native RVOT, 1/9 with a Melody® valve in each PA, 1/9 in a Contegra VenPro™, 2/9 in a Hancock® bioprosthesis, 2/9 in a pulmonary homograft); a Contegra VenPro™ in 6/16 (37%); and a BioPulmonic Valve™ in 1/16 (6%).</p><p>Diagnosis of IE was 58.1<!--> <!-->±<!--> <!-->34.3<!--> <!-->months after last intervention/surgery and delay from diagnosis of IE to emergency percutaneous treatment was 9.8<!--> <!-->±<!--> <!-->13.5<!--> <!-->days. Clinical presentation was obstructive cardiogenic shock in 50%, septic shock in 25% or fever/shivering with severe RVOTO in 25%. At time of intervention 68% had an active bacteremia. On echo RVOT velocity was 4.6<!--> <!-->±<!--> <!-->0.4<!--> <!-->m/s and RV function was severely reduced in 68%.</p><p>Procedural time was 76<!--> <!-->±<!--> <!-->48<!--> <!-->min. Invasive RV-systolic-pressure 86<!--> <!-->±<!--> <!-->21<!--> <!-->mmHg, mean-PA pressure 19<!--> <!-->±<!--> <!-->5<!--> <!-->mmHg, and systolic-aortic-pressure 95<!--> <!-->±<!--> <!-->13<!--> <!-->mmHg. Procedural approach (<span><span>Table 1</span></span>) was dilatation in 3 patients, uncovered-stent implantation in 5, covered-stent implantation in 7, Melody® valve in 1.</p><p>Immediate resolution of the RVOTO was obtained in all patients. Post-procedural systolic-RV-pressure was 42<!--> <!-->±<!--> <!-->11<!--> <!-->mmHg, while RVOT systolic gradient was 19<!--> <!-->±<!--> <!-->7<!--> <!-->mmHg. There were no periprocedural deaths but one severe complication (rupture of a tricuspid valve corda, repaired with the following surgery).</p><p>Surgical repair (68%) and percutaneous pulmonary valve implantation (18%) were performed after 12<!--> <!-->±<!--> <!-->34 months. One patient died of IE relapse after 3-months and one during surgery. One had cardiac transplantation due to uncontrolled sepsis.</p></div><div><h3>Conclusion</h3><p>Emergency interventional relieve of RVOTO was effective in all patients and permitted to delay pulmonary valve replacement in these critically ill patients.</p></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Interventional treatment of acute right ventricular outflow track (RVOT) infectious endocarditis as bridge to surgery or percutaneous pulmonary valve implantation\",\"authors\":\"A. Callegari , M. Albertini , L. Iserin , D. Bonnet , S. Malekzadeh-Milani\",\"doi\":\"10.1016/j.acvd.2024.07.029\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Infectious endocarditis (IE) is life threatening after pulmonary valve replacement. In case of obstructive cardiogenic shock or severe RVOTO an emergency percutaneous treatment can allow clinical stabilization to delay valve replacement.</p></div><div><h3>Objective</h3><p>This study aims to assess procedural success and clinical outcome in 16 consecutive patients (mean<!--> <!-->±<!--> <!-->SD age 27.2<!--> <!-->±<!--> <!-->15.7) with IE and primary percutaneous treatment.</p></div><div><h3>Methods</h3><p>Patients were retrospectively included.</p></div><div><h3>Results</h3><p>IE affected a Melody® valve in 9/16 (57%) cases (3/9 in a native RVOT, 1/9 with a Melody® valve in each PA, 1/9 in a Contegra VenPro™, 2/9 in a Hancock® bioprosthesis, 2/9 in a pulmonary homograft); a Contegra VenPro™ in 6/16 (37%); and a BioPulmonic Valve™ in 1/16 (6%).</p><p>Diagnosis of IE was 58.1<!--> <!-->±<!--> <!-->34.3<!--> <!-->months after last intervention/surgery and delay from diagnosis of IE to emergency percutaneous treatment was 9.8<!--> <!-->±<!--> <!-->13.5<!--> <!-->days. Clinical presentation was obstructive cardiogenic shock in 50%, septic shock in 25% or fever/shivering with severe RVOTO in 25%. At time of intervention 68% had an active bacteremia. On echo RVOT velocity was 4.6<!--> <!-->±<!--> <!-->0.4<!--> <!-->m/s and RV function was severely reduced in 68%.</p><p>Procedural time was 76<!--> <!-->±<!--> <!-->48<!--> <!-->min. Invasive RV-systolic-pressure 86<!--> <!-->±<!--> <!-->21<!--> <!-->mmHg, mean-PA pressure 19<!--> <!-->±<!--> <!-->5<!--> <!-->mmHg, and systolic-aortic-pressure 95<!--> <!-->±<!--> <!-->13<!--> <!-->mmHg. Procedural approach (<span><span>Table 1</span></span>) was dilatation in 3 patients, uncovered-stent implantation in 5, covered-stent implantation in 7, Melody® valve in 1.</p><p>Immediate resolution of the RVOTO was obtained in all patients. Post-procedural systolic-RV-pressure was 42<!--> <!-->±<!--> <!-->11<!--> <!-->mmHg, while RVOT systolic gradient was 19<!--> <!-->±<!--> <!-->7<!--> <!-->mmHg. There were no periprocedural deaths but one severe complication (rupture of a tricuspid valve corda, repaired with the following surgery).</p><p>Surgical repair (68%) and percutaneous pulmonary valve implantation (18%) were performed after 12<!--> <!-->±<!--> <!-->34 months. One patient died of IE relapse after 3-months and one during surgery. One had cardiac transplantation due to uncontrolled sepsis.</p></div><div><h3>Conclusion</h3><p>Emergency interventional relieve of RVOTO was effective in all patients and permitted to delay pulmonary valve replacement in these critically ill patients.</p></div>\",\"PeriodicalId\":55472,\"journal\":{\"name\":\"Archives of Cardiovascular Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Cardiovascular Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S187521362400250X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Cardiovascular Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S187521362400250X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Interventional treatment of acute right ventricular outflow track (RVOT) infectious endocarditis as bridge to surgery or percutaneous pulmonary valve implantation
Introduction
Infectious endocarditis (IE) is life threatening after pulmonary valve replacement. In case of obstructive cardiogenic shock or severe RVOTO an emergency percutaneous treatment can allow clinical stabilization to delay valve replacement.
Objective
This study aims to assess procedural success and clinical outcome in 16 consecutive patients (mean ± SD age 27.2 ± 15.7) with IE and primary percutaneous treatment.
Methods
Patients were retrospectively included.
Results
IE affected a Melody® valve in 9/16 (57%) cases (3/9 in a native RVOT, 1/9 with a Melody® valve in each PA, 1/9 in a Contegra VenPro™, 2/9 in a Hancock® bioprosthesis, 2/9 in a pulmonary homograft); a Contegra VenPro™ in 6/16 (37%); and a BioPulmonic Valve™ in 1/16 (6%).
Diagnosis of IE was 58.1 ± 34.3 months after last intervention/surgery and delay from diagnosis of IE to emergency percutaneous treatment was 9.8 ± 13.5 days. Clinical presentation was obstructive cardiogenic shock in 50%, septic shock in 25% or fever/shivering with severe RVOTO in 25%. At time of intervention 68% had an active bacteremia. On echo RVOT velocity was 4.6 ± 0.4 m/s and RV function was severely reduced in 68%.
Procedural time was 76 ± 48 min. Invasive RV-systolic-pressure 86 ± 21 mmHg, mean-PA pressure 19 ± 5 mmHg, and systolic-aortic-pressure 95 ± 13 mmHg. Procedural approach (Table 1) was dilatation in 3 patients, uncovered-stent implantation in 5, covered-stent implantation in 7, Melody® valve in 1.
Immediate resolution of the RVOTO was obtained in all patients. Post-procedural systolic-RV-pressure was 42 ± 11 mmHg, while RVOT systolic gradient was 19 ± 7 mmHg. There were no periprocedural deaths but one severe complication (rupture of a tricuspid valve corda, repaired with the following surgery).
Surgical repair (68%) and percutaneous pulmonary valve implantation (18%) were performed after 12 ± 34 months. One patient died of IE relapse after 3-months and one during surgery. One had cardiac transplantation due to uncontrolled sepsis.
Conclusion
Emergency interventional relieve of RVOTO was effective in all patients and permitted to delay pulmonary valve replacement in these critically ill patients.
期刊介绍:
The Journal publishes original peer-reviewed clinical and research articles, epidemiological studies, new methodological clinical approaches, review articles and editorials. Topics covered include coronary artery and valve diseases, interventional and pediatric cardiology, cardiovascular surgery, cardiomyopathy and heart failure, arrhythmias and stimulation, cardiovascular imaging, vascular medicine and hypertension, epidemiology and risk factors, and large multicenter studies. Archives of Cardiovascular Diseases also publishes abstracts of papers presented at the annual sessions of the Journées Européennes de la Société Française de Cardiologie and the guidelines edited by the French Society of Cardiology.